Cargando…
The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma
This study aimed to explore the significance and prognostic value of serum tumor-associated carbohydrate antigen 19-9 (CA19-9), D-dimer, and tumor necrosis factor alpha-induced protein 3 (TNFAIP3/A20) in patients with pancreatic ductal adenocarcinoma (PDAC). Our study included 148 patients treated f...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545421/ https://www.ncbi.nlm.nih.gov/pubmed/33578593 http://dx.doi.org/10.1097/MD.0000000000024651 |
_version_ | 1785114667737153536 |
---|---|
author | Xu, Peng Wang, XiaoDong Qian, JianJun Li, ZhengNan Yao, Jie Xu, AMan |
author_facet | Xu, Peng Wang, XiaoDong Qian, JianJun Li, ZhengNan Yao, Jie Xu, AMan |
author_sort | Xu, Peng |
collection | PubMed |
description | This study aimed to explore the significance and prognostic value of serum tumor-associated carbohydrate antigen 19-9 (CA19-9), D-dimer, and tumor necrosis factor alpha-induced protein 3 (TNFAIP3/A20) in patients with pancreatic ductal adenocarcinoma (PDAC). Our study included 148 patients treated for PDAC at Northern Jiangsu People's Hospital Affiliated to Yangzhou University from January 2012 to December 2016. Cutoff prognostic values were predicted using the receiver operating characteristic (ROC) curve. The Kaplan–Meier method was used to assess the survival rates of patients. Univariate and multivariate COX regression analyses were used to evaluate the prognostic factors. The recommended cutoff values of neutrophil–lymphocyte rate (NLR), platelet-lymphocyte rate (PLR), CA19-9, and D-dimer were 2.04 (sensitivity, 0.59; specificity, 0.9; area under the ROC curve [AUC], 0.749; P < .001), 52.94 (sensitivity, 0.73; specificity, 0.95; AUC, 0.829; P < .001), 176.66 U/mL (sensitivity, 0.7; specificity, 0.9; AUC, 0.794; P < .001), and 1.18 mg/L (sensitivity, 0.82; specificity, 0.9; AUC, 0.845; P < .001), respectively. Positive TNFAIP3/A20 expression was considered as an inclusion criterion. Serum CA19-9 expression was related with lymph node metastasis (P = .010), tumor-lymph node-metastasis (TNM) stage (P < .001), and survival rate (P < .001). D-dimer was correlated with tumor differentiation grade (P = .014), tumor size (P = .045), TNM stage (P < .001), and survival rate (P < .001). TNFAIP3/A20 was correlated with tumor differentiation grade (P < .001), body mass index (BMI) (P < .001), TNM stage (P = .014), and survival rate (P < .001). Kaplan–Meier curves showed that PDAC patients had significant differences in CA19-9, D-dimer, and TNFAIP3/A20 expressions (P < .05). CA19-9, D-dimer, TNM stage, tumor differentiation grade, and TNFAIP3/A20 were independent prognostic markers for PDAC in univariate and multivariate COX analyses. CA19-9, D-dimer, and TNFAIP3/A20 were found to be independent prognostic markers for PDAC patients. |
format | Online Article Text |
id | pubmed-10545421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-105454212023-10-03 The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma Xu, Peng Wang, XiaoDong Qian, JianJun Li, ZhengNan Yao, Jie Xu, AMan Medicine (Baltimore) 5700 This study aimed to explore the significance and prognostic value of serum tumor-associated carbohydrate antigen 19-9 (CA19-9), D-dimer, and tumor necrosis factor alpha-induced protein 3 (TNFAIP3/A20) in patients with pancreatic ductal adenocarcinoma (PDAC). Our study included 148 patients treated for PDAC at Northern Jiangsu People's Hospital Affiliated to Yangzhou University from January 2012 to December 2016. Cutoff prognostic values were predicted using the receiver operating characteristic (ROC) curve. The Kaplan–Meier method was used to assess the survival rates of patients. Univariate and multivariate COX regression analyses were used to evaluate the prognostic factors. The recommended cutoff values of neutrophil–lymphocyte rate (NLR), platelet-lymphocyte rate (PLR), CA19-9, and D-dimer were 2.04 (sensitivity, 0.59; specificity, 0.9; area under the ROC curve [AUC], 0.749; P < .001), 52.94 (sensitivity, 0.73; specificity, 0.95; AUC, 0.829; P < .001), 176.66 U/mL (sensitivity, 0.7; specificity, 0.9; AUC, 0.794; P < .001), and 1.18 mg/L (sensitivity, 0.82; specificity, 0.9; AUC, 0.845; P < .001), respectively. Positive TNFAIP3/A20 expression was considered as an inclusion criterion. Serum CA19-9 expression was related with lymph node metastasis (P = .010), tumor-lymph node-metastasis (TNM) stage (P < .001), and survival rate (P < .001). D-dimer was correlated with tumor differentiation grade (P = .014), tumor size (P = .045), TNM stage (P < .001), and survival rate (P < .001). TNFAIP3/A20 was correlated with tumor differentiation grade (P < .001), body mass index (BMI) (P < .001), TNM stage (P = .014), and survival rate (P < .001). Kaplan–Meier curves showed that PDAC patients had significant differences in CA19-9, D-dimer, and TNFAIP3/A20 expressions (P < .05). CA19-9, D-dimer, TNM stage, tumor differentiation grade, and TNFAIP3/A20 were independent prognostic markers for PDAC in univariate and multivariate COX analyses. CA19-9, D-dimer, and TNFAIP3/A20 were found to be independent prognostic markers for PDAC patients. Lippincott Williams & Wilkins 2021-02-12 /pmc/articles/PMC10545421/ /pubmed/33578593 http://dx.doi.org/10.1097/MD.0000000000024651 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 5700 Xu, Peng Wang, XiaoDong Qian, JianJun Li, ZhengNan Yao, Jie Xu, AMan The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma |
title | The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma |
title_full | The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma |
title_fullStr | The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma |
title_full_unstemmed | The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma |
title_short | The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma |
title_sort | prognostic evaluation of ca19-9, d-dimer and tnfaip3/a20 in patients with pancreatic ductal adenocarcinoma |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545421/ https://www.ncbi.nlm.nih.gov/pubmed/33578593 http://dx.doi.org/10.1097/MD.0000000000024651 |
work_keys_str_mv | AT xupeng theprognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma AT wangxiaodong theprognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma AT qianjianjun theprognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma AT lizhengnan theprognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma AT yaojie theprognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma AT xuaman theprognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma AT xupeng prognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma AT wangxiaodong prognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma AT qianjianjun prognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma AT lizhengnan prognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma AT yaojie prognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma AT xuaman prognosticevaluationofca199ddimerandtnfaip3a20inpatientswithpancreaticductaladenocarcinoma |